Table 5.
Univariate analyses of determining factors that affect VTE development in patients with lymphoid malignancies
| Factor | Univariate analysis | |
|---|---|---|
| Odds Ratio (95% CI) | P value | |
| Sex (male) | 0.65 (0.38‐1.12) | .1208 |
| Age | 1.00 (0.98‐1.11) | .9610 |
| Aggressive lymphoma: DLBCL | 2.03 (1.14‐3.61) | .0157 |
| Advanced diseasea | 1.61 (0.94‐2.77) | .0844 |
| Extranodal localization | 1.71 (0.99‐2.92) | .0507 |
| Systemic symptoms | 0.90 (0.52‐1.55) | .6940 |
| Mediastinal involvement | 4.34 (2.21‐8.53) | .0001 |
| High‐risk diseaseb | 0.90 (0.52‐1.55) | .6940 |
| Previous VTE/AMI/stroke | 3.08 (1.42‐6.68) | .0045 |
| Reduced mobility (ECOG 2‐4) | 3.77 (1.19‐11.92) | .0238 |
| Neutrophils <1 × 109/L | 0.95 (0.21‐4.33) | .9432 |
| Prechemotherapy platelet count >350 × 109/L | 1.15 (0.63‐2.12) | .6495 |
| Prechemotherapy leukocyte count >11 × 109/L | 1.81 (1.01‐3.26) | .0474 |
| Prechemotherapy hemoglobin <100 g/L | 0.48 (0.23‐1.01) | .0526 |
| High ThroLy scorec | 5.97 (2.16‐16.52) | .0006 |
| Intermediate ThroLy scorec | 3.94 (2.18‐7.09) | .0001 |
a
Advanced disease: stage according to Lugano IV.
b
IPI, International Prognostic Index ≥3; IPS, International Prognostic Score ≥3.
According to the ThroLy score; high risk (Score > 3).
c
According to the ThroLy score; intermediate risk (Score 2 – 3).
P < .05‐statistically significant.
CI, confidence interval.